Nuventra Ranks on Inc. 5000 List for Eighth Consecutive Year
Nuventra is proud to announce that it has once again been ranked on the Inc. 5000 list for 2021. This marks the eighth year in a row that Nuventra has…
Read More
CATO SMS Acquires Nuventra to Expand Drug Development Offering Into Clinical Pharmacology
CATO SMS, a global provider of regulatory and clinical research services, announced today that it has acquired Nuventra to extend its offering into the critical area of clinical pharmacology. Headquartered…
Read More
Nuventra Announces PK/PD Innovation Fellowship with UNC Chapel Hill for the Advancement of Minorities in the Pharmaceutical Sciences
Nuventra is pleased to announce a partnership with the University of North Carolina at Chapel Hill for the joint training of clinical pharmacologists. The PK/PD Innovation Fellowship is open to…
Read More
Nuventra Client G1 Therapeutics Receives FDA Approval for COSELA™
Nuventra is pleased to congratulate its client, G1 Therapeutics, on the approval of COSELA™ (trilaciclib). The drug is the first therapy in its class to reduce the frequency of chemotherapy-induced…
Read More
Nuventra to Present and Exhibit at ASCPT Annual Meeting
Nuventra is proud to announce its participation at this year’s ASCPT Annual Meeting. The meeting will be held virtually from March 8–12 and March 15–17, 2021. Nuventra’s CSO and ASCPT’s…
Read More
Nuventra to Speak at PBSS Symposium on Cardiac Safety for Preclinical and Clinical Development
Nuventra’s Associate Director of Clinical Pharmacology, Lauren R. L. Lohmer, Ph.D., will be presenting during the upcoming PBSS San Francisco Symposium titled, “Cardiac Safety from Preclinical to the Clinic: Industry…
Read More
Nuventra Pharma Sciences Appoints Daniel Roy, M.H.A, as President
Nuventra Pharma Sciences announced today that Daniel Roy, M.H.A., has been appointed to the role of President. Mr. Roy joined Nuventra in 2014 as Manager of Marketing and Corporate Communication.…
Read More